For Andreas Dreps, ICON’s senior vice president, oncology drug development, many of the most exciting developments in oncology are in the area of cell and gene therapy. • Read the full article ...

Icon Oncology is proud to announce the opening of applications for its 2025 Social Grants Programme, a key initiative aimed at fostering growth within the oncology and supporting services ...

Raymond James analyst Laura Prendergast downgraded Mural Oncology (MURA) to Outperform from Strong Buy with an $18 price target Light Up your ...

Icon has begun the integration of Medidata Clinical Data Studio into its clinical studies. This development makes Icon the ...

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ: ICLR) a world-leading clinical research ...

A 2024 ICON survey of over 100 oncology developers’ pipelines reflected a diverse and highly complex landscape of emerging precision oncology therapies. These emerging therapies in oncology are ...